Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/min

Liver International

Volumn 36, Issue 6, 2016, Pages 798-801

  Nazario, Hector E ^a   Ndungu, Milka ^a   Modi, Apurva A ^b  

^a METHODIST DALLAS MEDICAL CENTER   (United States)

^b Liver Consultants of Texas   (United States)

Author keywords

Chronic hepatitis C; Cirrhosis; End stage renal disease; Kidney transplant; Liver transplantation; Renal failure; Severe renal impairment; Simeprevir; Sofosbuvir

Indexed keywords

SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; END STAGE RENAL DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HEADACHE; HEMODIALYSIS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INSOMNIA; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; NAUSEA; TREATMENT OUTCOME; CHRONIC HEPATITIS C; CHRONIC KIDNEY FAILURE; COMBINATION DRUG THERAPY; COMPLICATION; GENETICS; HEPACIVIRUS; MIDDLE AGED; SUSTAINED VIROLOGIC RESPONSE; TEXAS;

AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; KIDNEY FAILURE, CHRONIC; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RENAL DIALYSIS; SIMEPREVIR; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; TEXAS;

EID: 84951191565     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13025     Document Type: Article

References (14)

1. Berenguer M. Treatment of chronic hepatitis C in hemodialysis patients. Hepatology 2008; 48: 1690-8.
2. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36: 3-10.
3. Fabrizi F, Takkouche B, Lunghi G, et al. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat 2007; 14: 697-703.
4. Fabrizi F, Martin P, Dixit V, Messa P. Meta-analysis of observational studies: hepatitis C and survival after renal transplant. J Viral Hepat 2013; 21: 314-24.
5. Baid-Agrawal S, Pascual M, Moradpour D, Somasundaram R, Muche M. Hepatitis C virus infection and kidney transplantation in 2014: what's new? Am J Transplant 2014; 14: 2206-20.
6. Xia Y, Friedmann P, Yaffe H, et al. Effect pf HCV, HIV and coinfection in kidney transplant recipients: mate kidney analyses. Am J Transplant 2014; 14: 2037-47.
7. Liu CH, Huang CF, Liu CJ, et al. Pegylated Interferon-2a with or without low-dose ribavirin for treatment-naïve patients with hepatitis C virus genotype 1 receiving hemodialysis. Ann Intern Med 2013; 159: 729-38.
8. Dumortier J, Guillaud O, Gagnieu MC, et al. Anti-viral triple therapy with telaprevir in haemodialyzsed HCV patients: is it feasible? J Clin Virol 2013; 56: 146-9.
9. Basu PP, Siriki R, Shah NJ, et al. Telaprevir with adjusted dose ribavirin in naïve CHC-G1: efficacy and treatment in CHC in hemodialysis population. TARGET-C (RCT). J Hepatol 2013; 58: S30-1.
10. Lemoinne S, Barrou B, Thabut D. Triple therapy for hepatitis C virus infection in patients receiving hemodialysis. Ann Intern Med 2014; 160: 851.
11. Lawitz E, Sulkowski M, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomized study. Lancet 2014; 384: 1756-65.
12. Goodkin DA, Bieber B, Gillespie B, Robinson BM, Jadoul M. Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol 2013; 38: 405-12.
13. Roth D, Nelson D, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naïve and treatment experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (C-SURFER Study): a combination phase 3 study. Lancet 2015; 6736: 1-9.
14. Pockros PJ, Reddy KR, Mantry PS, et al. Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-1 Study. [Abstract] 50th Annual Meeting of European Association for the Study of the Liver (EASL). 2015; S257.